Efgartigimod alfa clinical trials
Also written Efgartigimod, ARGX-113 and Vyvgart.
How each study uses efgartigimod alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the efgartigimod alfa studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 17 Dec 2021 · VYVGART · BLA 761195 (FDA, Drugs@FDA)
- European Union
- 10 Aug 2022 · Vyvgart · EMEA/H/C/005849 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
65 studies that test it; most in 2025 (14); 1 more planned to start later
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 6 |
| 2021 | 7 |
| 2022 | 2 |
| 2023 | 9 |
| 2024 | 12 |
| 2025 | 14 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 48 · Other 18
argenx (48) · Shanghai Zhongshan Hospital (2) · Stanford University (1) · Beijing Tiantan Hospital (1) · M. Peter Marinkovich (1) · University of South Florida (1) · Zhongming Qiu (1) · First Affiliated Hospital of Wenzhou Medical University (1)
Often tested with
Tested in the same studies.
Hyaluronidase (human recombinant) (22) · Thymectomy (1) · Telitacicept (1) · Methylprednisolone (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Efgartigimod alfa is the comparator. A study of two new drugs counts under both.
- 1Nipocalimab · Janssen Research & Development, LLC · next primary completion Sep 2027
Reaching primary completion within a year · 14, 6 in phase 3
Studies that test efgartigimod alfa, phase 3 first.
- Jan 2027Efgartigimod in IVIG Dependent Myasthenia Gravis PatientsPhase 3 · Clinique Neuro-Outaouais
- Mar 2027Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia GravisPhase 2/3 · argenx
- Jun 2027EFG vs IVIG in TAMGPhase 3 · Shanghai Zhongshan Hospital
- Jul 2027A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's SyndromePhase 3 · argenx
- Sep 2027A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia GravisPhase 2/3 · argenx
- Oct 2027A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune ThrombocytopeniaPhase 3 · argenx
- Dec 2026Perioperative Efgartigimod for Thymoma and Myasthenia GravisPhase 2 · Shanghai Zhongshan Hospital
- Dec 2026Efgartigimod for Stiff Person Syndrome (ESPS)Phase 2 · University of South Florida
- Dec 2026Treatment of Myasthenia Gravis Exacerbation or Crisis With EfgartigimodPhase 4 · University of Colorado, Denver
- Mar 2027A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic SclerosisPhase 2 · argenx
Studies
Open first, then newest update. How each study uses efgartigimod alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 66
- A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)RecruitingPhase 2/3argenxNCT07194850Written as Efgartigimod IV
- A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' DiseaseRecruitingPhase 3argenxNCT07570316Written as Efgartigimod PH20 SC
- A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.RecruitingPhase 3argenxNCT07596849Written as efgartigimod PH20 SC
- Efgartigimod for the Treatment of Acute Optic NeuritisRecruitingPhase 2Anastasia Vishnevetsky, MD, MPHNCT06453694Written as Efgartigimod Alfa
- Efgartigimod in IVIG Dependent Myasthenia Gravis PatientsRecruitingPhase 3Clinique Neuro-OutaouaisNCT06765161Written as efgartigimod administration
- A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory MyopathyEnrolling by invitationPhase 3argenxNCT05979441Written as Efgartigimod PH20 SC
- A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia GravisRecruitingPhase 2/3argenxNCT06392386Written as Efgartigimod PH20 SC
- ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to EfgartigimodRecruitingPhase 2argenxNCT07284420Written as Efgartigimod IV
- A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and AdultsNot yet recruitingPhase 2argenxNCT07583641Written as Efgartigimod PH20 (ARGX-113) SC
- Efficacy and Safety of Efgartigimod in the Treatment of Guillain-Barré Syndrome(GREAT)Not yet recruitingPhase 2Beijing Tiantan HospitalNCT07806916Written as Efgartigimod Alfa-Fcab
- Efgartigimod in Anti-NMDA Receptor Encephalitis.RecruitingPhase 2Beijing Tongren HospitalNCT07822776Written as Efgartigimod Alfa
- Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC EfgartigimodRecruitingPhase 4Centre Hospitalier Universitaire de NiceNCT07072988Written as Efgartigimod
- A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)Not yet recruitingPhase 2argenxNCT07760818Written as efgartigimod PH20 SC
- A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)RecruitingPhase 2University of MinnesotaNCT06831058Written as efgartigimod
- Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)Not yet recruitingPhase 1/2M. Peter MarinkovichNCT07011589Written as Efgartigimod
- A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune ThrombocytopeniaRecruitingPhase 3argenxNCT06544499Written as Efgartigimod IV
- A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)RecruitingPhase 4argenxNCT06909214Written as Efgartigimod PH20 SC
- EFG vs IVIG in TAMGNot yet recruitingPhase 3Shanghai Zhongshan HospitalNCT07231523Written as Efgartigimod + Thymectomy
- Treatment of Myasthenia Gravis Exacerbation or Crisis With EfgartigimodRecruitingPhase 4University of Colorado, DenverNCT06860633Written as Efgartigimod
- Efgartigimod for Stiff Person Syndrome (ESPS)Not yet recruitingPhase 2University of South FloridaNCT06528392Written as Efgartigimod
See all 66 studies that test efgartigimod alfa →
As the comparator · 1 — what is tested is compared with efgartigimod alfa
Codes
What other systems call efgartigimod alfa · ClinicalTrials.gg INT001674
- MeSH (NLM) C000718373efgartigimod alfaConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 961YV2O515EFGARTIGIMOD ALFAConfirmed FDA, NLM, Wikidata
- RxNorm 2587717One source FDA
- Wikidata Q110271677efgartigimod alfaConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171817Efgartigimod AlfaOne source FDA
- DrugBank DB15270One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718373 | efgartigimod alfa | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 961YV2O515 | EFGARTIGIMOD ALFA | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2587717 | — | One source FDA |
| Wikidata | Q110271677 | efgartigimod alfa | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171817 | Efgartigimod Alfa | One source FDA |
| DrugBank | DB15270 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.